ArticleCancer management and research2018
Prognostic values of HE4 expression in patients with cancer: a meta-analysis.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.Technology in cancer research & treatmentPooled it
- Protein Glycosylation as Biomarkers in Gynecologic Cancers.Diagnostics (Basel, Switzerland) · 2022Review
- Current and Emerging Prognostic Biomarkers in Endometrial Cancer.Frontiers in oncology · 2022Review
- The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.Frontiers in medicine · 2022Review
- HE4 as a Biomarker for Endometrial Cancer.Cancers · 2021Review
- Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?Diagnostics (Basel, Switzerland) · 2021Article
- Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.Journal of ovarian research · 2021Article
- Diagnostic value of human epididymis protein 4 in malignant pleural effusion in lung cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Meta-analysis of the prognostic role of HE4 expression in cancer patients: clinical insights into interpretation of clinical outcomes.Cancer management and research · 2019Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the prognostic impact of HE4 expression in patients with cancer. MATERIALS AND
methodsWe searched the PubMed, Web of Science, Chinese National Knowledge Infrastructure and WangFang databases for publications concerning HE4 expression in patients with cancer. The correlation of HE4 expression level with overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) was analyzed.
resultsIn this meta-analysis, 29 studies, with a total of 4,235 patients, were included. Our results showed that HE4 expression was significantly associated with poorer OS (hazard ratio [HR] =2.15, 95% confidence interval [CI] =1.77-2.62,
conclusionThese results suggest that expression of HE4 was associated with a worse prognosis in patients with cancer. HE4 is a potential novel prognostic factor in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.